search

Active clinical trials for "Muscular Atrophy"

Results 101-110 of 458

Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease

Pompe Disease (Late-onset)Inclusion Body Myositis2 more

The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD). The secondary objectives are to evaluate whether muscle pain is associated with muscle function, to assess whether muscle pain is associated with alterations of muscle tissue, and whether vitamin D metabolism and polymorphisms of ACE and ACTN3 genes may contribute to an increased level of perceived musculoskeletal pain. In a second step, exome sequencing of genes associated with musculoskeletal pain will be analyzed. Results of LOPD patients will be compared to patients with neuromuscular disorders with a similar distribution of muscle weakness and/or musculoskeletal pain.

Recruiting6 enrollment criteria

Improving Standards of Care and Translational Research in Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

The SMA REACH UK Network is a national and international partnership between doctors and therapists involved in the care of children and adults with Spinal Muscular Atrophy. This network is supported by Biogen and SMA UK.

Recruiting2 enrollment criteria

Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal...

MyopathyMuscle Weakness6 more

Visits to the emergency department (ED) for chest pain are extremely common and require a safe, rapid and efficacious treatment algorithm to exclude a possible AMI. These diagnostic algorithms are partly based on an important laboratory value, which showed growing utility in the diagnostic and prognostic of many cardiovascular diseases in the last years : cardiac troponin. However, some patients with muscle disease often present with unexplained elevated high-sensitive cardiac Troponin T (hs-cTnT) levels in the absence of cardiac disease. The investigators aim at the characterization of the behaviour of this biomarker and its alternative (high-sensitive cardiac Troponin I), which will have important clinical implications on patients management.

Recruiting6 enrollment criteria

NuroSleeve Powered Brace & Stimulation System to Restore Arm Function

Neurologic DiseasesHemiparesis12 more

The purpose of this study is to investigate if a person with weakness or paralysis in one or both arms, can use the NuroSleeve combined powered arm brace (orthosis) and muscle stimulation system to help restore movement in one arm sufficient to perform daily activities. This study could lead to the development of a product that could allow people with arm weakness or arm paralysis to use the NuroSleeve and similar devices to improve arm health and independent function.

Recruiting24 enrollment criteria

The Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture

Hip FracturesMuscle Atrophy

The investigators aim to study the use of blood flow restriction therapy (BFR) to augment routine post-operative physical therapy in elderly patients (age >= 65) after recovering from surgical treatment of hip fractures.

Active28 enrollment criteria

Long Term Trajectories of SMA Patients Receiving or Not Disease-modifying Treatments

Spinal Muscular Atrophy

This is an observational multicenter retrospective and prospective study on natural history of SMA also considering the 'new natural history' secondary to the availability of commercially available therapies. All the patients enrolled to date in the Italian registry, if not part of clinical trials, will be included in the present study.

Recruiting2 enrollment criteria

Natural History of SMA

Muscular AtrophySpinal

This is an investigator initiated observational study with the aim to record several aspects of function, care and adverse events in a large cohort of SMA patients followed longitudinally by using a structured academic disease registry.

Recruiting2 enrollment criteria

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention...

Muscular AtrophySpinal

This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children < 2 years of age genetically diagnosed with SMA.

Not yet recruiting14 enrollment criteria

NM Balance Regulation With ULLS and Loss of Sleep

Muscle WeaknessQuadriceps Muscle Atrophy1 more

The goal of this trial is to learn about how restricted sleep and not bearing weight on the leg affects muscle strength and posture control. Participants will walk exclusively on one leg, sleep at differing intervals, and complete posture tests, muscle strength tests, and muscle imaging. Researchers will compare adequate sleep and restricted sleep to see if muscle strength and posture are affected.

Recruiting22 enrollment criteria

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. Until recently, the mainstay of treatment for these patients was supportive medical care. However, advances in medical treatment focusing on gene replacement, gene enhancement, motor neuron protection and muscle enhancement is likely to change the management and prognosis of these patients in the future. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options.

Recruiting4 enrollment criteria
1...101112...46

Need Help? Contact our team!


We'll reach out to this number within 24 hrs